613 related articles for article (PubMed ID: 19793708)
1. Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.
Ault P; Jones K
Clin J Oncol Nurs; 2009 Oct; 13(5):511-7. PubMed ID: 19793708
[TBL] [Abstract][Full Text] [Related]
2. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
3. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E
Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
[TBL] [Abstract][Full Text] [Related]
4. Iron overload and toxicity: the hidden risk of multiple blood transfusions.
Shander A; Cappellini MD; Goodnough LT
Vox Sang; 2009 Oct; 97(3):185-97. PubMed ID: 19663936
[TBL] [Abstract][Full Text] [Related]
5. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias.
Kwiatkowski JL; Cohen AR
Hematol Oncol Clin North Am; 2004 Dec; 18(6):1355-77, ix. PubMed ID: 15511620
[TBL] [Abstract][Full Text] [Related]
6. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
Dreyfus F
Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
[TBL] [Abstract][Full Text] [Related]
7. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
8. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
Takatoku M; Uchiyama T; Okamoto S; Kanakura Y; Sawada K; Tomonaga M; Nakao S; Nakahata T; Harada M; Murate T; Ozawa K;
Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
[TBL] [Abstract][Full Text] [Related]
9. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox (Exjade) for the treatment of iron overload.
Cappellini MD; Taher A
Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation therapy for patients with myelodysplastic syndrome.
Yeh SP; Yang YS; Yao CY; Peng CT
Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
[TBL] [Abstract][Full Text] [Related]
12. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias.
Ho PJ; Tay L; Lindeman R; Catley L; Bowden DK
Intern Med J; 2011 Jul; 41(7):516-24. PubMed ID: 21615659
[TBL] [Abstract][Full Text] [Related]
13. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
14. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy.
Shander A; Sazama K
Transfusion; 2010 May; 50(5):1144-55. PubMed ID: 20088842
[TBL] [Abstract][Full Text] [Related]
15. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
Mittelman M; Lugassy G; Merkel D; Tamary H; Sarid N; Rachmilewitz E; Hershko C; ;
Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
[No Abstract] [Full Text] [Related]
16. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
Imran F; Phatak P
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
[TBL] [Abstract][Full Text] [Related]
17. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
Jabbour E; Kantarjian HM; Koller C; Taher A
Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
[TBL] [Abstract][Full Text] [Related]
18. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
Chacko J; Pennell DJ; Tanner MA; Hamblin TJ; Wonke B; Levy T; Thomas PW; Killick SB
Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
[TBL] [Abstract][Full Text] [Related]
19. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in improving the management of sickle cell disease.
Inati A
Blood Rev; 2009 Dec; 23 Suppl 1():S9-13. PubMed ID: 20116638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]